Aurobindo Pharma Board to Consider Q2 Results and Interim Dividend
Aurobindo Pharma Ltd 路 Intimation 路 04 Nov 2026, 5:30 am
Aurobindo Pharma Board to Consider Q2 Results and Interim Dividend Aurobindo Pharma's Board of Directors is scheduled to meet on 4th Nov'26 to consider and approve the standalone and consolidated unaudited financial results for the second quarter and half year ended 30th Sep'26. Additionally, the board will evaluate the declaration of an interim dividend for FY27. In compliance with insider trading regulations, the company's trading window remains closed until 6th Nov'26 and will reopen on 7th Nov'26.
Original exchange filing (PDF)
More announcements from Aurobindo Pharma Ltd
- Intimation of classification of US FDA inspection at Lannet Company LLC, a wholly owned subsidiary of Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company. 路 12 Nov 2026
- Submission of Earning Call Transcript for Q2FY27. 路 11 Nov 2026
- Unit-2 of Apitoria Pharma Private Limited, a wholly owned subsidiary of the Company received Establishment Inspection Report from US FDA with classification as "Voluntary Action Indicated". 路 11 Nov 2026
- Intimation of investors / analysts meet to be held on 17.11.2026. 路 09 Nov 2026
- Intimation of investor / analysts meet to be held on 16.09.2026. 路 09 Nov 2026
- Submission of Financial results for the Quarter and Half year ended September 30, 2026. 路 05 Nov 2026
- Reappointment of Mr. M. R. Kumar as Independent Director of the Company for second term with effect from April 1, 2027. 路 05 Nov 2026
- Transfer of ownership of Auro Pharma LLC, Russia from Auroactive Pharma Private Limited to Auropharm Overseas Limited, Wholly Owned subsidiaries of the Company. 路 05 Nov 2026
